Irritable Bowel Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Af

Published Jun 30, 2025

Length 200 Pages

SKU # FCSL20159960

Description

The global irritable bowel syndrome (IBS) treatment market is on a high-growth trajectory, fueled by rising prevalence, technological integration, and increased investment in gastrointestinal healthcare. IBS, characterized by recurring abdominal discomfort, bloating, constipation, and diarrhea, is becoming a major health challenge worldwide. Increasing awareness and the development of effective treatment options are significantly contributing to the market’s expansion.

Market Insights

The IBS treatment market is expected to grow from US$ 4 billion in 2025 to US$ 7.54 billion by 2032, expanding at a robust CAGR of 9.48%. This growth is largely driven by a combination of heightened diagnostic rates, evolving treatment methods, and the rising adoption of digital health tools to manage and monitor IBS symptoms.

New therapies, including microbiome-targeted treatments and gut-brain axis modulators, are making significant headway. Meanwhile, advancements in drug delivery systems and extended-release formulations are improving therapeutic efficacy and patient compliance.

Key Market Drivers
• Rising Global Incidence of IBS: A growing number of people globally are being diagnosed with IBS, particularly in urban regions with high stress levels and poor dietary habits.
• Improved Patient Awareness: Educational campaigns and digital platforms are encouraging patients to seek timely medical intervention for IBS symptoms.
• Advanced Drug Therapies: The market is seeing a rise in the use of medications like Linaclotide and other agents that enhance gut motility and reduce discomfort.
• Integration of Digital Healthcare: The use of smartphone apps, wearable tracking devices, and teleconsultations is helping deliver more personalized and accessible care.
• Emphasis on Gut Health and Microbiome Research: Breakthroughs in gut microbiome science are enabling targeted and non-invasive treatment approaches.

Business Opportunities

Pharmaceutical companies are capitalizing on the growing demand by investing heavily in the development of innovative therapies. The emergence of personalized treatment plans that include a combination of probiotics, dietary changes, and advanced pharmacological therapies is creating significant commercial potential.

Retail pharmacies are becoming a preferred channel for distribution, thanks to their accessibility and consumer trust. The recent availability of over-the-counter options, like probiotics and Linaclotide, is also enhancing patient reach and supporting market penetration.

Regional Analysis

North America continues to lead the global IBS treatment market. Strong healthcare infrastructure, expanded insurance coverage, and the availability of advanced diagnostic tools are driving growth in this region. The region is also witnessing increased adoption of digital health technologies and targeted therapies, supporting better patient outcomes.

Asia Pacific is emerging as a high-growth region with rising healthcare investments and awareness. Governments in countries such as China, India, and Japan are launching national initiatives to address gut health. Integration of modern diagnostics, coupled with increasing prevalence of IBS, is making the region a key growth hotspot. The market in Asia Pacific is supported by better access to healthcare and the rollout of digital platforms that assist in symptom monitoring and treatment planning.

Key Growth Drivers

Several global players are actively engaged in product innovation, strategic collaborations, and market expansion. The competitive Analysis is marked by mergers, acquisitions, and the introduction of patient-centric solutions aimed at improving the standard of care.

Key companies include:
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Abbott Laboratories
• Novartis AG
• AstraZeneca PLC
• Ironwood Pharmaceuticals Inc.
• Allergan Plc
• Bausch Health Companies Inc.
• GlaxoSmithKline Plc
• Lexicon Pharmaceuticals Inc.
• Sucampo Pharmaceuticals Inc.

Recent industry activities include the launch of comprehensive IBS care programs, advanced clinical trials for new treatments, and strategic acquisitions aimed at enhancing therapeutic pipelines.

Market Segmentation

By Product
• Fiber Supplements
• Anti-Diarrheal
• Anticholinergic and Antispasmodic Agents
• Antidepressants
• Antibiotics
• Alosetron
• Lubiprostone
• Linaclotide
• NHE3 Inhibitors

By Indication
• IBS with Constipation (IBS-C)
• IBS with Diarrhoea (IBS-D)
• IBS with Alternating Constipation and Diarrhoea

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies and E-commerce Platforms
• Hypermarkets and Supermarkets

By Region
• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America

Please note: Delivery Timelines - 5 working days.

1. Executive Summary: 1.1. Global Irritable Bowel Syndrome Treatment Market Snapshot; 1.2. Future Projections; 1.3. Key Market Trends; 1.4. Regional Snapshot, by Value, 2025; 1.5. Analyst Recommendations
2. Market Overview: 2.1. Market Definitions and Segmentations; 2.2. Market Dynamics; 2.2.1. Drivers; 2.2.2. Restraints; 2.2.3. Market Opportunities; 2.3. Value Chain Analysis; 2.4. Porter’s Five Forces Analysis; 2.5. COVID-19 Impact Analysis; 2.5.1. Supply; 2.5.2. Demand; 2.6. Impact of Ukraine-Russia Conflict; 2.7. Economic Overview; 2.7.1. World Economic Projections; 2.8. PESTLE Analysis
3. Global Irritable Bowel Syndrome Treatment Market Outlook, 2019-2032: 3.1. Global Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032; 3.1.1. Key Highlights; 3.1.1.1. Fiber Supplements; 3.1.1.2. Anti-Diarrheal; 3.1.1.3. Anticholinergic and Antispasmodic; 3.1.1.4. Antidepressant; 3.1.1.5. Antibiotics Antibiotics; 3.1.1.6. Alosetron; 3.1.1.7. Lubiprostone; 3.1.1.8. Linaclotide; 3.1.1.9. NHE3; 3.2. Global Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032; 3.2.1. Key Highlights; 3.2.1.1. Irritable Bowel Syndrome with Constipation; 3.2.1.2. Irritable Bowel Syndrome with Diarrhoea; 3.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea; 3.3. Global Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032; 3.3.1. Key Highlights; 3.3.1.1. Hospital Pharmacies; 3.3.1.2. Retail Pharmacies; 3.3.1.3. Drug Stores; 3.3.1.4. Online Pharmacies and Stores; 3.3.1.5. Hypermarkets and Supermarkets; 3.4. Global Irritable Bowel Syndrome Treatment Market Outlook, by Region, Value (US$ Bn), 2019-2032; 3.4.1. Key Highlights; 3.4.1.1. North America; 3.4.1.2. Europe; 3.4.1.3. Asia Pacific; 3.4.1.4. Latin America; 3.4.1.5. Middle East & Africa
4. North America Irritable Bowel Syndrome Treatment Market Outlook, 2019-2032: 4.1. North America Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032; 4.1.1. Key Highlights; 4.1.1.1. Fiber Supplements; 4.1.1.2. Anti-Diarrheal; 4.1.1.3. Anticholinergic and Antispasmodic; 4.1.1.4. Antidepressant; 4.1.1.5. Antibiotics Antibiotics; 4.1.1.6. Alosetron; 4.1.1.7. Lubiprostone; 4.1.1.8. Linaclotide; 4.1.1.9. NHE3; 4.2. North America Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032; 4.2.1. Key Highlights; 4.2.1.1. Irritable Bowel Syndrome with Constipation; 4.2.1.2. Irritable Bowel Syndrome with Diarrhoea; 4.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea; 4.3. North America Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032; 4.3.1. Key Highlights; 4.3.1.1. Hospital Pharmacies; 4.3.1.2. Retail Pharmacies; 4.3.1.3. Drug Stores; 4.3.1.4. Online Pharmacies and Stores; 4.3.1.5. Hypermarkets and Supermarkets; 4.4. North America Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032; 4.4.1. Key Highlights; 4.4.1.1. U.S. Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 4.4.1.2. U.S. Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 4.4.1.3. U.S. Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 4.4.1.4. Canada Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 4.4.1.5. Canada Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 4.4.1.6. Canada Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Irritable Bowel Syndrome Treatment Market Outlook, 2019-2032: 5.1. Europe Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032; 5.1.1. Key Highlights; 5.1.1.1. Fiber Supplements; 5.1.1.2. Anti-Diarrheal; 5.1.1.3. Anticholinergic and Antispasmodic; 5.1.1.4. Antidepressant; 5.1.1.5. Antibiotics Antibiotics; 5.1.1.6. Alosetron; 5.1.1.7. Lubiprostone; 5.1.1.8. Linaclotide; 5.1.1.9. NHE3; 5.2. Europe Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032; 5.2.1. Key Highlights; 5.2.1.1. Irritable Bowel Syndrome with Constipation; 5.2.1.2. Irritable Bowel Syndrome with Diarrhoea; 5.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea; 5.3. Europe Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032; 5.3.1. Key Highlights; 5.3.1.1. Hospital Pharmacies; 5.3.1.2. Retail Pharmacies; 5.3.1.3. Drug Stores; 5.3.1.4. Online Pharmacies and Stores; 5.3.1.5. Hypermarkets and Supermarkets; 5.4. Europe Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032; 5.4.1. Key Highlights; 5.4.1.1. Germany Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 5.4.1.2. Germany Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 5.4.1.3. Germany Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 5.4.1.4. U.K. Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 5.4.1.5. U.K. Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 5.4.1.6. U.K. Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 5.4.1.7. France Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 5.4.1.8. France Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 5.4.1.9. France Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 5.4.1.10. Italy Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 5.4.1.11. Italy Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 5.4.1.12. Italy Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 5.4.1.13. Turkey Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 5.4.1.14. Turkey Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 5.4.1.15. Turkey Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 5.4.1.16. Russia Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 5.4.1.17. Russia Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 5.4.1.18. Russia Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 5.4.1.19. Rest of Europe Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 5.4.1.20. Rest of Europe Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 5.4.1.21. Rest of Europe Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, 2019-2032: 6.1. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032; 6.1.1. Key Highlights; 6.1.1.1. Fiber Supplements; 6.1.1.2. Anti-Diarrheal; 6.1.1.3. Anticholinergic and Antispasmodic; 6.1.1.4. Antidepressant; 6.1.1.5. Antibiotics Antibiotics; 6.1.1.6. Alosetron; 6.1.1.7. Lubiprostone; 6.1.1.8. Linaclotide; 6.1.1.9. NHE3; 6.2. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032; 6.2.1. Key Highlights; 6.2.1.1. Irritable Bowel Syndrome with Constipation; 6.2.1.2. Irritable Bowel Syndrome with Diarrhoea; 6.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea; 6.3. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032; 6.3.1. Key Highlights; 6.3.1.1. Hospital Pharmacies; 6.3.1.2. Retail Pharmacies; 6.3.1.3. Drug Stores; 6.3.1.4. Online Pharmacies and Stores; 6.3.1.5. Hypermarkets and Supermarkets; 6.4. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032; 6.4.1. Key Highlights; 6.4.1.1. China Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 6.4.1.2. China Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 6.4.1.3. China Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 6.4.1.4. Japan Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 6.4.1.5. Japan Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 6.4.1.6. Japan Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 6.4.1.7. South Korea Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 6.4.1.8. South Korea Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 6.4.1.9. South Korea Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 6.4.1.10. India Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 6.4.1.11. India Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 6.4.1.12. India Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 6.4.1.13. Southeast Asia Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 6.4.1.14. Southeast Asia Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 6.4.1.15. Southeast Asia Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 6.4.1.16. Rest of Asia Pacific Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 6.4.1.17. Rest of Asia Pacific Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 6.4.1.18. Rest of Asia Pacific Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Irritable Bowel Syndrome Treatment Market Outlook, 2019-2032: 7.1. Latin America Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032; 7.1.1. Key Highlights; 7.1.1.1. Fiber Supplements; 7.1.1.2. Anti-Diarrheal; 7.1.1.3. Anticholinergic and Antispasmodic; 7.1.1.4. Antidepressant; 7.1.1.5. Antibiotics Antibiotics; 7.1.1.6. Alosetron; 7.1.1.7. Lubiprostone; 7.1.1.8. Linaclotide; 7.1.1.9. NHE3; 7.2. Latin America Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032; 7.2.1. Key Highlights; 7.2.1.1. Irritable Bowel Syndrome with Constipation; 7.2.1.2. Irritable Bowel Syndrome with Diarrhoea; 7.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea; 7.3. Latin America Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032; 7.3.1. Key Highlights; 7.3.1.1. Hospital Pharmacies; 7.3.1.2. Retail Pharmacies; 7.3.1.3. Drug Stores; 7.3.1.4. Online Pharmacies and Stores; 7.3.1.5. Hypermarkets and Supermarkets; 7.4. Latin America Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032; 7.4.1. Key Highlights; 7.4.1.1. Brazil Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 7.4.1.2. Brazil Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 7.4.1.3. Brazil Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 7.4.1.4. Mexico Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 7.4.1.5. Mexico Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 7.4.1.6. Mexico Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 7.4.1.7. Argentina Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 7.4.1.8. Argentina Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 7.4.1.9. Argentina Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 7.4.1.10. Rest of Latin America Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 7.4.1.11. Rest of Latin America Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 7.4.1.12. Rest of Latin America Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, 2019-2032: 8.1. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032; 8.1.1. Key Highlights; 8.1.1.1. Fiber Supplements; 8.1.1.2. Anti-Diarrheal; 8.1.1.3. Anticholinergic and Antispasmodic; 8.1.1.4. Antidepressant; 8.1.1.5. Antibiotics Antibiotics; 8.1.1.6. Alosetron; 8.1.1.7. Lubiprostone; 8.1.1.8. Linaclotide; 8.1.1.9. NHE3; 8.2. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032; 8.2.1. Key Highlights; 8.2.1.1. Irritable Bowel Syndrome with Constipation; 8.2.1.2. Irritable Bowel Syndrome with Diarrhoea; 8.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea; 8.3. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032; 8.3.1. Key Highlights; 8.3.1.1. Hospital Pharmacies; 8.3.1.2. Retail Pharmacies; 8.3.1.3. Drug Stores; 8.3.1.4. Online Pharmacies and Stores; 8.3.1.5. Hypermarkets and Supermarkets; 8.4. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032; 8.4.1. Key Highlights; 8.4.1.1. GCC Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 8.4.1.2. GCC Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 8.4.1.3. GCC Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 8.4.1.4. South Africa Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 8.4.1.5. South Africa Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 8.4.1.6. South Africa Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 8.4.1.7. Egypt Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 8.4.1.8. Egypt Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 8.4.1.9. Egypt Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 8.4.1.10. Nigeria Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 8.4.1.11. Nigeria Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 8.4.1.12. Nigeria Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 8.4.1.13. Rest of Middle East & Africa Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032; 8.4.1.14. Rest of Middle East & Africa Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2019-2032; 8.4.1.15. Rest of Middle East & Africa Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2019-2032; 8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape: 9.1. Product vs Distribution Channel Heatmap; 9.2. Manufacturer vs Distribution Channel Heatmap; 9.3. Company Market Share Analysis, 2025; 9.4. Competitive Dashboard; 9.5. Company Profiles; 9.5.1. Takeda Pharmaceutical Company Limited; 9.5.1.1. Company Overview; 9.5.1.2. Product Portfolio; 9.5.1.3. Financial Overview; 9.5.1.4. Business Strategies and Development; 9.5.2. Pfizer, Inc.; 9.5.2.1. Company Overview; 9.5.2.2. Product Portfolio; 9.5.2.3. Financial Overview; 9.5.2.4. Business Strategies and Development; 9.5.3. Abbott Laboratories; 9.5.3.1. Company Overview; 9.5.3.2. Product Portfolio; 9.5.3.3. Financial Overview; 9.5.3.4. Business Strategies and Development; 9.5.4. Novartis AG; 9.5.4.1. Company Overview; 9.5.4.2. Product Portfolio; 9.5.4.3. Financial Overview; 9.5.4.4. Business Strategies and Development; 9.5.5. AstraZeneca PLC; 9.5.5.1. Company Overview; 9.5.5.2. Product Portfolio; 9.5.5.3. Financial Overview; 9.5.5.4. Business Strategies and Development; 9.5.6. Ironwood Pharmaceuticals Inc. and Allergan Plc; 9.5.6.1. Company Overview; 9.5.6.2. Product Portfolio; 9.5.6.3. Financial Overview; 9.5.6.4. Business Strategies and Development; 9.5.7. Bausch Health Companies Inc.; 9.5.7.1. Company Overview; 9.5.7.2. Product Portfolio; 9.5.7.3. Financial Overview; 9.5.7.4. Business Strategies and Development; 9.5.8. GlaxoSmithKline Plc.; 9.5.8.1. Company Overview; 9.5.8.2. Product Portfolio; 9.5.8.3. Financial Overview; 9.5.8.4. Business Strategies and Development; 9.5.9. Lexicon Pharmaceuticals Inc.; 9.5.9.1. Company Overview; 9.5.9.2. Product Portfolio; 9.5.9.3. Financial Overview; 9.5.9.4. Business Strategies and Development; 9.5.10. Sucampo Pharmaceuticals Inc.; 9.5.10.1. Company Overview; 9.5.10.2. Product Portfolio; 9.5.10.3. Financial Overview; 9.5.10.4. Business Strategies and Development
10. Appendix: 10.1. Research Methodology; 10.2. Report Assumptions; 10.3. Acronyms and Abbreviations

Pricing

Currency Rates

Single User Email from Publisher $4,995
Global Site License Email from Publisher $10,600

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now